RASSF1A启动子甲基化作为子宫内膜癌生物标志物的潜力:系统综述与Meta分析
该系统综述与Meta分析纳入8篇文章,计算RASSF1A启动子甲基化与子宫内膜癌关联的合并OR及95%CI并按种族亚组分析。总体OR为11.46,欧洲人群OR为15.07,异质性经离群值处理后消失且关联仍显著,作者认为RASSF1A具有良好的生物标志物潜力。
要点
- RASSF1A启动子甲基化与子宫内膜癌风险升高相关,总体OR为11.46。
- 欧洲人群OR为15.07,亚洲人群离群值处理后OR为23.74(P≤0.0001)。
- 离群值处理后异质性消失(I2=0%),关联显著性保留,支持其生物标志物潜力。
核心结论
- RASSF1A启动子甲基化与子宫内膜癌风险升高存在一致的关联,且具有统计学显著性和稳健性,作者认为其具有良好的子宫内膜癌生物标志物潜力。
研究设计与样本
- 系统综述与Meta分析,文献检索共纳入8篇文章,计算合并OR及95%CI,并按种族进行亚组分析,采用离群值分析探究异质性来源。
主要发现
- 总体效应OR为11.46;欧洲人群OR为15.07;两者均存在异质性(I2=57-70%),经离群值处理后异质性消失(I2=0%)且保留显著性(OR 9.85-12.66),离群值处理前后P≤0.0001。
- 亚洲人群离群值处理前OR为6.85,存在异质性(I2=82%),未达统计学显著(P=0.12);离群值处理后异质性消失(I2=0%)并产生显著性(OR 23.74,P≤0.0001)。
关键数值与推荐
- 总体合并OR为11.46;欧洲人群OR为15.07;亚洲人群离群值处理前OR为6.85(P=0.12),离群值处理后OR为23.74(P≤0.0001)。
- 总体与欧洲人群离群值处理后OR为9.85-12.66,P≤0.0001,异质性I2=0%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文报告总体效应与欧洲人群结果存在异质性(I2=57-70%)。
- 原文报告亚洲人群离群值处理前结果存在异质性(I2=82%)且未达统计学显著(P=0.12)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An epigenetic approach to explaining endometrial carcinogenesis necessitates good understanding of Ras association domain family 1 isoform A (RASSF1A) promoter methylation data from primary studies. AIMS: Differential magnitude of reported associations between RASSF1A promoter methylation and endometrial cancer (EC) prompted a meta-analysis to obtain more precise estimates. METHODS: Literature search yielded eight included articles. We calculated pooled odds ratios (OR) and 95% confidence intervals and subgrouped the data by race. Sources of heterogeneity were investigated with outlier analysis. RESULTS: The pooled ORs indicated increased risk, mostly significant. The overall effect (OR 11.46) was reflected in the European outcome (OR 15.07). However, both findings were heterogeneous (I2=57-70%) which when subjected to outlier treatment, erased heterogeneity (I2=0%) and retained significance (OR 9.85-12.66). Significance of these pre- and post-outlier outcomes were pegged at P≤0.0001. Only the Asian pre-outlier (OR 6.85) and heterogeneous (I2=82%) outcome was not significant (P=0.12) but when subjected to outlier treatment, erased heterogeneity (I2=0%) and generated significance (OR 23.74, P≤0.0001). CONCLUSIONS: Consistent increased risk associations underpinned by significance and robustness render RASSF1A with good biomarker potential for EC.
引用
- Pabalan N, Kunjantarachot A, Ruangpratheep C, et al. Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2017. PMID: 28669560. doi:10.1016/j.ygyno.2017.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。